SOPHiA AI makes Data-Driven Medicine more valuable by combining genomics and radiomics to fight cancer
Mountain View – USA, 24th January 2018, SOPHiA GENETICS announced from the Precision Medicine World Conference (PMWC) in Silicon Valley that its artificial intelligence, SOPHiA, has gained radiomics capabilities. Merging for the first-time genomics and radiomics is a watershed moment in the field of Data-Driven Medicine which will profoundly enhance patient care.
Already deployed in 400 teaching hospitals across 5 continents, to help clinicians analyze the genomic profile of a patient every 5 minute, SOPHiA has proven to be a solid decision support technology for geneticists and pathologists. With this additional capability in radiomics, the company’s technology will further empower clinicians in oncology, cardiology and neurology. It will also help better monitor disease progression and treatment efficacy.
In Oncology, SOPHiA’s new capabilities to combine radiomics and genomics is used during the whole patient care path and will immediately impact in the context of virtual tumor boards. Patient management in oncology includes many interdependent steps between disease assessment, diagnosis, therapy and monitoring. The aim is to make this process seamless by providing integrated solutions that help specialists make complex decisions.
Radiomics capabilities integrated to SOPHiA AI are based on mechanistic and mathematical modelling and help to predict the evolution of a tumor (size, volume and location) by analyzing quantitative image features from two or more consecutive standard-of-care medical images (i.e. PET-scans, MRIs, x-rays and more). Clinical proofs of concept have already been executed on hundreds of patients’ cases for lung, kidney, glioma and meningioma and the technology should soon be applied to any solid tumor.
Dr. Jurgi Camblong, CEO and cofounder of the company comments from PMWC:
“This groundbreaking development comes at a pivotal moment and is aligned to the company’s vision to help oncology enter the era of real-time epidemiology. An era where we will be able to cluster patients’ cancer cases in virtual cohorts and predict that the cancer of a patient looks like the one of 10’000 other patients and that the most effective treatment has proven to be X or Y. This era requires real-world evidence data and a large network. Already used and trusted by over 400 teaching hospitals, SOPHiA has the capability of being at the core of a collective intelligence that will help diagnose and treat patients precisely and equally around the world.”